Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/07/24
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueBusiness Wire • 04/25/24
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceBusiness Wire • 04/09/24
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Business Wire • 04/01/24
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety TreatmentsSeeking Alpha • 03/17/24
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?Zacks Investment Research • 02/21/24
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateBusiness Wire • 02/13/24
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024Business Wire • 02/06/24
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic PainBusiness Wire • 12/27/23